Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
NCT02465515
Completed
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/11/2019
Locations: GSK Investigational Site, Rapid City, South Dakota +1 locations
Conditions: Diabetes Mellitus
Register for Updates
Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only
NCT00518115
Completed
This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus who are either taking no diabetes medication or who are taking metformin only. This study will investigate the safety, tolerability, and efficacy of Albiglutide (GSK716155) and will measure the levels of Albiglutide (GSK716155) in the bloodstream when it is given for 16 weeks. As a comparison, some subjects will receive exenatide instead of Albiglutide (GSK716155). The study will involve weekly visits for 17 weeks... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/03/2016
Locations: GSK Investigational Site, Watertown, South Dakota
Conditions: Diabetes Mellitus, Type 2
Register for Updates